Akari Therapeutics PLC - American Depositary Shares (AKTX) closed at $8.58 on October 27, 2026, up 12.5% from the previous close, on volume of 38,453 shares (30-day average 48,082).
Data as of October 27, 2026.
27-Oct-2026
Globe Newswire (Thu, 15-Oct 9:20 AM ET)
AKTX Names Vatnak Vat-Ho as CBO as It Pushes AKTX-101 Toward a Mid-2027 First-in-Human Goal
Market Chameleon (Wed, 14-Oct 7:16 AM ET)
Globe Newswire (Tue, 13-Oct 9:01 AM ET)
Globe Newswire (Thu, 1-Oct 8:25 AM ET)
Globe Newswire (Tue, 8-Sep 9:15 AM ET)
Akari Therapeutics Participates in the Virtual Investor "Why Now" On-Demand Conference
Globe Newswire (Thu, 27-Aug 9:01 AM ET)
JTC Team Releases Virtual Investor "Why Now" On-Demand Conference Featuring Nine Public Company CEOs
ACCESS Newswire (Thu, 27-Aug 9:01 AM ET)
Globe Newswire (Tue, 18-Aug 8:53 AM ET)
Globe Newswire (Thu, 13-Aug 4:15 PM ET)
Globe Newswire (Tue, 4-Aug 8:50 AM ET)
Akari Therapeutics PLC is an oncology company developing next-generation antibody-drug conjugates (ADCs) built around novel, proprietary payloads utilizing powerful biology to attack cancer. Its payload, PH1, targets RNA splicing by modulating the spliceosome, a complex machinery in the cell that converts pre-RNA into spliced RNA for translation into vital proteins for cell survival and growth. Its product pipeline is AKTX-101, which targets the Trop2 receptor on cancer cells and, with a proprietary linker, enables it to deliver its novel PH1 payload directly into the tumor with minimal off-target effects. and AKTX-102, an ADC candidate targeting CEACAM5 (Carcinoembryonic Antigen-related Cell Adhesion Molecule-5), a well-validated tumor antigen expressed across multiple solid tumors.
Akari Therapeutics PLC - American Depositary Shares trades on the NASDAQ stock market under the symbol AKTX.
As of October 27, 2026, AKTX stock price climbed to $8.58 with 38,453 million shares trading.
AKTX has a beta of 3.37, meaning it tends to be more sensitive to market movements. AKTX has a correlation of 0.04 to the broad based SPY ETF.
AKTX has a market cap of $19.61 million. This is considered a Sub-Micro Cap stock.
In the last 3 years, AKTX traded as high as $176.00 and as low as $3.02.
AKTX has underperformed the market in the last year with a return of -71.0%, while the SPY ETF gained +14.8%. In the last 3 month period, AKTX fell short of the market, returning -1.4%, while SPY returned +4.4%. However, in the most recent 2 weeks AKTX has outperformed the stock market by returning +0.5%, while SPY returned -1.1%.
AKTX support price is $6.95 and resistance is $8.32 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that AKTX shares will trade within this expected range on the day.
